The cost of a new randomized trial to evaluate the vaccine’s ability to prevent disease could run into tens of millions of ...

U.S. Health Secretary Robert F. Kennedy Jr. told a personal story of his heroin addiction, spiritual awakening and recovery ...

Anti-IL1RAP ADC demonstrated potent anti-tumor efficacy and was well tolerated in pre-clinical modelsAnti-IL1RAP ADC targets IL1RAP, which is overexpressed in many tumors and their tumor microenvironm ...

CatalYm today announced the presentation of the first preclinical data demonstrating that the company’s clinical-stage ...

Delgocitinib cream had superior efficacy and a better safety profile compared with oral alitretinoin for the treatment of ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the U.S. Food and Drug Administration (FDA) ...

A new study on Lyme disease sheds light on the persistence of symptoms; another new study points to an antibiotic that may be ...

You have probably heard the term “ultra-processed food.” What does that mean? Unprocessed food probably requires little explanation. For example, ...

Mice overcame a Lyme disease infection after being given an antibiotic that is often used for pneumonia, and its effect on ...

Corcept sees 40% growth in 2025 revenue with promising trials, expanded patient base, and strong projections. Read my ...

Novo Nordisk (NYSE: NVO) stock hit an all-time high of $148.15 in June 2024, marking a remarkable fivefold surge since 2019.

Qure's AMT-130 gene therapy for Huntington’s Disease shows promising trial data. Check out my recommendation for QURE stock.